OSUR

Business Context and Reporting Period

Company: OraSure Technologies, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2007
Business Overview: OraSure develops, manufactures, and markets oral fluid diagnostic products and specimen collection devices. Key product lines include the OraQuick ADVANCE rapid HIV-1/2 test, OraSure/Intercept oral fluid collection devices for HIV and drug testing, and cryosurgical systems for wart removal. The company operates in the United States and internationally, selling to clinical laboratories, hospitals, public health organizations, and the over-the-counter (OTC) market.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Total revenues increased 21% to $82.7 million, driven by a 23% increase in infectious disease testing sales (primarily OraQuick HIV tests) and a 36% increase in cryosurgical systems sales.
• Profitability Decline: Despite revenue growth, Net Income decreased 53% to $2.5 million. This was primarily due to a 63% increase in Research and Development (R&D) expenses to $14.1 million, focused on OTC HIV and HCV test development.
• Margin Compression: Gross margin declined from 64% to 61% due to increased scrap expenses, higher product support costs, and a less favorable product mix.
• Customer Concentration: Abbott Laboratories and Quest Diagnostics accounted for 10% and 11% of total revenues, respectively, in 2007.

Guidance, Outlook, and Risks

Management Commentary and Outlook

• R&D Focus: Management expects R&D costs to increase by approximately $7.0 million in 2008, driven by clinical trials for the OraQuick HIV OTC test and the OraQuick HCV test.
• OTC Strategy: The company is aggressively pursuing FDA approval to sell the OraQuick HIV test in the U.S. OTC market. Clinical work is expected to continue through 2008.
• Distribution Changes: The distribution agreement with Prestige Brands for the U.S. OTC cryosurgical market terminated on December 31, 2007, following an arbitration ruling. The company is evaluating alternative distribution strategies for this market.
• Supply Chain: The company secured a two-year supply of HIV-1 antigen from bioMerieux (BMX) to manufacture Western blot tests after BMX discontinued its screening test and terminated distribution agreements.

Risks and Contingencies

• Regulatory Approvals: Future success depends on obtaining FDA approval for OTC HIV testing and HCV testing. Delays or failures could significantly reduce future revenues.
• Shelf Life: The current six-month shelf life of the OraQuick HIV test limits international sales and OTC potential. Extension to 12 months is required for full market penetration but is not guaranteed.
• Legal Proceedings: A patent infringement lawsuit against Schering-Plough was settled in January 2008, resulting in a license for Schering-Plough and a $4.9 million payment to OraSure (to be recorded in Q1 2008).
• Competition: The company faces intense competition from larger firms and "home-brew" assays developed by laboratory customers, particularly in the drug testing and insurance risk assessment markets.

Key Facts for Investor Verification

• OTC HIV Approval Status: Verify the timeline and progress of clinical trials for the OraQuick HIV-1/2 OTC application, as this is a primary growth driver.
• OTC Cryosurgical Replacement: Confirm the status of new distribution agreements to replace the terminated Prestige Brands contract in the U.S. and Canadian markets.
• BMX Antigen Supply: Monitor the sufficiency of the purchased HIV-1 antigen inventory and the progress of seeking FDA approval for an alternative screening test for the OraSure device.
• R&D Spend vs. Milestones: Track the $7.0 million projected increase in 2008 R&D spend against the achievement of regulatory milestones for HCV and OTC HIV products.
• Deferred Tax Assets: Note the $45.5 million in federal NOL carryforwards and the company's assessment of their realizability against future taxable income.